Vmbook Online ordering

Pharmacyclics Inc

Pacira BioSciences, Inc. (PCYC) is a US-based public company that specializes in the development, manufacture, and commercialization of novel therapeutics targeting the hospital market. The company's lead product is EXPAREL® (bupivacaine liposome injectable suspension), an innovative non-opioid local analgesic indicated for the management of post-surgical pain.

Let's discuss Pacira BioSciences' key aspects:

A. Company Overview:

* Founded in 1994, headquartered in Parsippany, New Jersey

* Initially focused on the development and commercialization of drugs for cancer pain

* Expanded portfolio to focus on non-opioid local analgesics and regenerative medicine

* Workforce of approximately 500 employees (2021 data)

B. Financials and Earnings:

* Q3 2022 revenue: $114.1 million (31% YoY growth)

* Net income Q3 2022: $26.1 million (compared to a loss of $12.9 million in Q3 2021)

* Full-year 2022 revenue guidance: $420-$430 million (26%-30% YoY growth)

* As of Q3 2022, Pacira BioSciences has a cash and short-term investment balance of $273.2 million

C. Growth and Business Developments:

* Continued expansion of EXPAREL's indications across multiple surgical settings (orthopedic, oral surgery, urology, gynecology, and others)

* Developing new applications of iovera°, a non-opioid, minimally invasive therapeutic tool for the treatment of chronic pain

* Continued commercialization of iovera° in the U.S. and Europe

* Collaboration with several pharmaceutical and biotech companies, such as Asahi Kasei Pharma, GSK, and Avanos Medical, for further expansion and growth

The company's strong performance in Q3 2022 and the increased full-year 2022 revenue guidance suggest an optimistic outlook for Pacira BioSciences. Their focus on non-opioid local analgesics aligns with current market demands and ongoing regulatory targets to reduce the dependency on opioids. Overall, Pacira BioSciences is a company to watch in the drug manufacturing and therapeutics sector.